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Consequences of Neonatal Hypoxic-Ischemic Brain Injury,
Reduces Interleukin-1 and Tumor Necrosis Factor-
mRNA Induction, and Does Not Affect Endothelial Nitric
Oxide Synthase Expression
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Background and Purpose—Prophylactic administration of simvastatin has been shown to protect against brain damage and
its long-lasting behavioral consequences in neonatal rats. To establish the drug treatment window, we evaluated the
effectiveness of simvastatin administered at different intervals before and after stroke. Furthermore, we determined
whether simvastatin affected endothelial nitric oxide synthase (eNOS) or inflammatory cytokines in brain tissue or
cholesterol levels in serum.
Methods—On postnatal day 7, male rats were subjected to hypoxia-ischemia (HI). The experiment included sham-operated
controls and HI animals receiving daily saline or activated simvastatin (20 mg/kg) injections from postnatal day 1 to day
7 (HI-simvastatin 1–7 group), from postnatal day 4 to day 11 (HI-simvastatin 4–11 group), or from postnatal day 7 to
day 14 (HI-simvastatin 7–14 group). The neuroprotective effect of simvastatin was evaluated at adulthood by means of
behavioral and histological analyses. Cytokines and eNOS expression were assessed by reverse transcriptase–
polymerase chain reaction and Western blotting.
Results—Animals in both the HI-simvastatin 1–7 and HI-simvastatin 4–11 groups performed better than HI rats in either
the T-maze or the circular water maze and showed significantly attenuated brain damage. Expression of interleukin-1
and tumor necrosis factor- mRNA in cortex was significantly increased in HI but not in HI-simvastatin 1–7 animals.
In the same brain area, simvastatin treatment did not affect the increase of eNOS expression observed after HI.
Conclusions—These findings indicate that prophylactic but not delayed administration of simvastatin improves functional
outcome in neonatal rat stroke. The reduced induction of cytokines suggests that the neuroprotective effect of
simvastatin may be related to a dampening of the inflammatory response. (Stroke. 2003;34:2007-2012.)
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The 3-hydroxy-3-methylglutaryl coenzyme A reductaseinhibitors (statins) are widely prescribed to lower cho-
lesterol in hyperlipidemic patients at risk of cardiovascular
diseases. A growing body of experimental and clinical
evidence, however, suggests that statins possess additional
properties that may confer to these drugs a direct neuropro-
tective effect in stroke.1–4
In adult animal models of experimental stroke, statins were
found to be neuroprotective, and this effect has been ascribed
to their ability to modulate endothelial nitric oxide synthase
(eNOS).5,6 Indeed, chronic treatment with simvastatin or
mevastatin upregulates eNOS activity in cells and improves
cerebral blood flow.5,6 Further important evidence of the role
of eNOS in the effect of statins is the finding that simvastatin
is not neuroprotective in eNOS-deficient mice, indicating that
increased eNOS activity may represent a mechanism against
cerebral injury.5 However, statins also possess additional
properties that could be related to their neuroprotective effect
in stroke. They were found to reduce vascular inflammatory
responses2,7; to ameliorate endothelial function4; to modulate
cytokine responses that occur during ischemia and reperfu-
sion by reducing the induction of inducible nitric oxide
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synthase (iNOS), interleukin-1 (IL-1), and tumor necrosis
factor- (TNF-) in astrocytes and macrophages8; and to
promote angiogenesis.9
Stroke can also occur in the perinatal period and generally
results in severe neurological deficits that span the individu-
al’s lifetime, including delayed mental and motor develop-
ment, epilepsy, and major cognitive deficits. Because of the
variations in the clinical presentation and diagnosis, the exact
incidence of perinatal stroke remains to be determined,
although estimates indicate that it can occur in approximately
1 in 4000 term births.10 Using a well-established animal
model for studying perinatal stroke, originally developed by
Rice et al,11 we recently reported that a prophylactic admin-
istration of simvastatin, a statin that crosses the blood-brain
barrier, significantly protected against brain damage and its
long-lasting behavioral consequences, indicating that the drug
is also effective in perinatal stroke.12 In the present report we
extend evidence of the neuroprotective effect of simvastatin
in this model of stroke. The aim of the study was 2-fold: (1)
to determine the effectiveness of simvastatin administered at
different times before and after the ischemic insult to estab-
lish a drug treatment window and (2) to evaluate whether a
prophylactic administration of simvastatin affected brain
eNOS, inflammatory cytokines, and serum cholesterol levels.
Materials and Methods
Animals, Drug Treatment and Cerebral
Hypoxia-Ischemia
All surgical and experimental procedures were performed in accor-
dance with the Italian regulations for the care and use of laboratory
animals. On postnatal day 7, Sprague-Dawley (Charles River, Italy)
pup rats were anesthetized with ether and subjected to ligation of the
right common carotid artery followed by 3 hours of hypoxia (92%
nitrogen and 8% oxygen), as previously described.12,13 Activated
simvastatin (20 mg/kg) was injected daily (subcutaneously) from
postnatal day 1 to day 7 (hypoxia-ischemia [HI]–simvastatin 1–7
group), from postnatal day 4 to day 11 (HI-simvastatin 4–11 group),
or from postnatal day 7 to day 14 (HI-simvastatin 7–14 group). The
HI-simvastatin 7–14 group received the first dose of the drug directly
after the period of hypoxia. Vehicle-treated sham-operated control
(control group) and HI-injured animals received a corresponding
volume of PBS from postnatal day 4 to day 11. We had previously
reported that simvastatin administration to control animals from
postnatal day 1 to day 7 did not result in long-lasting behavioral
deficits and that the decrease in body weight observed during
treatment and at weaning was completely recovered in adulthood.12
Thus, in our experimental protocol we did not include a control
group of animals treated with simvastatin.
Two ischemic animals, 1 from group HI-simvastatin 1–7 and 1
from group HI-simvastatin 7–14, died during the period of hypoxia.
To avoid variability in the growth rate among treatments, the number
of animals in every experimental group was reduced from 8 to 7.
Rectal temperatures were measured before surgery and at the end
of the period of hypoxia; no differences were found among groups
(data not shown).
Reverse transcriptase–polymerase chain reaction (RT-PCR) and
Western blot analyses were performed in additional groups of
sham-operated (control), HI, and HI-simvastatin 1–7 rats (n5 per
group). Control and HI animals were treated from postnatal day 1 to
day 7 with vehicle. Behavioral and histological measurements were
performed by investigators blinded to the experimental conditions.
Left and Right Choices in a T-Maze
At postnatal day 28, each animal was given 3 trials in a T-maze, and
the number of left or right choices was recorded.13 The test was
repeated for 3 consecutive days.
Circular Water Maze
Animals were trained in a circular maze12 and evaluated in a
training-to-criterion test. The animal was placed in the water within
the quadrant opposite the one containing the pedestal (placed 30 cm
from the edge of the tank equidistant from the edges of the quadrant)
and facing the wall of the pool. If the animal located and climbed
onto the pedestal, it was permitted 30 seconds on the pedestal before
the next trial started. If the animal did not find the pedestal within
120 seconds, it was placed directly on the pedestal and allowed a
30-second rest period. The performance criterion was 3 trials in a
row with an average time before escape of 20 seconds. When the
animal reached the criterion, it was transferred to the next location on
the next day. Each animal received a maximum of 32 trials for each
of the 2 positions of the pedestal. Data are expressed as the number
of sessions needed to reach the criterion.
Histology
Histological analysis was performed at the end of the behavioral
experiments, as previously described.12 Measurements included only
intact tissue determined on the basis of the intensity and uniformity
of the staining.
RNA Extraction and RT-PCR Analysis
Total RNA was extracted from rat cortex according to the acid
guanidinium-phenol-chloroform method.14 For transcription, total
RNA (0.8 g) was used as a substrate for single-stranded cDNA
synthesis with the use of the Gene Amp RNA PCR Kit (Perkin
Elmer), according to the manufacturer’s instructions. An aliquot (10
L) of cDNA synthesis mix was used for the PCR reaction.
Gene-specific oligonucleotide primers were as follows (forward and
reverse, 5-3): CCAGGATTCATGTGCCAGG and CCACT-
CAGTCTTGGCAGTGC (product size: 191) for cyclophilin; CTC-
CATGAGCTTTGTACAAGG and TGCTGATGTACCAGTT-
GGGG (product size: 245) for IL-1; TCAGCCTCTTCT-
CATTCCTGC and TTGGTGGTTTGCTACGACGTG (product
size: 203) for TNF-; and GAAAACAGAGCTTCAGCATGCT-
TGG and TTTGAGTGTCACGTAGGCTTCTATGC (product size:
543) for interleukin-10 (IL-10). PCRs were conducted in a Perkin
Elmer Gene Amp 9700 System. After an initial denaturation at 95°C
for 5 minutes, amplification was conducted through 22 to 36 cycles
of denaturation at 94°C for 30 seconds, annealing at 55°C (60°C for
IL-10) for 30 seconds, and extension at 72°C for 30 seconds. Final
extension was at 72°C for 7 minutes. Initial experiments were
conducted to determine the optimal annealing temperature for each
set of gene-specific primers and the linear phase of the product
amplification (data not shown). In each PCR (RNA extraction,
cDNA synthesis, and PCR), negative and positive controls were
included. A portion of the PCR mixture (7 L) was electrophoresed
in a 1.5% (wt/vol) agarose gel, stained with ethidium bromide. The
relative intensity of the bands was measured by an Image Quant
Analyzer (Molecular Dynamics) The level of gene expression of
each transcript was normalized to that of the reporter gene
cyclophilin.
Western Blot Analysis
This analysis was performed on ischemic and contralateral cortices
of rats in the HI and HI-simvastatin 1–7 groups or the whole cortex
of controls. Samples (50 g protein; Bradford dye-binding proce-
dure, Bio-Rad Laboratories) were separated onto 6% sodium dodecyl
sulfate–polyacrylamide gel, and proteins were transferred to a
nitrocellulose membrane (40 mA, overnight, 4°C). Blots were
probed with monoclonal eNOS primary antibody (1:2000; Transduc-
tion Laboratories), processed with horseradish peroxidase–conju-
gated anti-mouse IgG (1:4000), and detected with the ECL system
(Amersham Pharmacia Biotech). A monoclonal antibody against
-actin (1:4000; Sigma) was used as a control for protein gel
loading. Western blot were analyzed with the use of NIH Image
software. Data were normalized to those of -actin and expressed as
percentage of control.
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Cholesterol Measurement
Serum total cholesterol was assayed by a standard enzymatic method
(Diagnostic Cholesterol kit; Sigma).
Data Analysis
Data are presented as meanSE. Statistical analyses were performed
with the Prism computer program (GraphPad Software Inc). Body
weight data were analyzed by 1-way ANOVA followed by the
Newman-Keuls multiple comparison test. T-maze, circular water
maze, Western blot, and RT-PCR data were analyzed with the
Kruskal-Wallis test followed by the Dunn multiple comparison test.
The Mann-Whitney U test was used to analyze data from brain
volume. Percent reduction in whole hemisphere or in selected brain
regions was calculated by the following formula: 100(left-sided
volumeright-sided volume)/left-sided volume. Statistical analysis
was performed by the Kruskal-Wallis test followed by the Dunn
multiple comparison test.
Results
Body weights for the different treatment groups were mea-
sured at weaning (21 days) and in the adult animals (80 days).
At weaning, the body weights of HI- and HI-simvastatin–
treated animals were significantly lower than those of the
control group (Figure 1A; P0.05). A progressive recovery
of body weight was observed after weaning, and at 80 days of
age no differences were found among groups (Figure 1B).
In agreement with our previous studies,12,13 ischemic rats,
when tested in the T-maze, preferentially chose the arm
ipsilateral to the damaged side (Figure 2; right/left ratio:
control, 1.290.21; HI, 4.140.69; P0.05). The right/left
ratio of all groups of HI-simvastatin–treated animals did not
differ from that of controls. In addition, the right/left ratio of
the HI-simvastatin 1–7 and HI-simvastatin 4–11 groups
differed significantly from that of the ischemic group
(P0.05).
Learning abilities were tested in a circular water maze
(Figure 3). Groups differed significantly in the number of
sessions required to find the submerged pedestal in both the
first and the second positions (P0.0027 and P0.042,
respectively). The post hoc test revealed that only the HI and
the HI-simvastatin 7–14 groups differed from controls
(P0.01 and P0.05, respectively, for the pedestal in posi-
tion 1 and P0.05 for the pedestal in position 2).
At the end of the behavioral tests, animals were killed and
evaluated for histological damage. The Table shows the
results of a quantitative evaluation of brain damage. Brain
injury was significantly attenuated in the HI-simvastatin 1–7
and HI-simvastatin 4–11 groups but not in the HI-simvastatin
7–14 group. This pattern was observed when histological
damage was measured with consideration of the whole
hemisphere, the cerebral cortex, or the hippocampus.
In adult animals statins upregulate eNOS expression, with
a subsequent amelioration of cerebral blood flow.5,15 We
therefore investigated whether a similar effect could be
observed after a prophylactic treatment with simvastatin in
brain tissue of HI immature animals. The pattern of eNOS
expression assessed by Western blotting in the cerebral cortex
at different times after the ischemic insult is shown in Figure
4. Expression of eNOS was significantly higher in the
ischemic side 24 hours after HI. However, the expression of
the protein in the HI-simvastatin 1–7 group did not differ
from that observed in HI animals.
Since statins modulate cytokine production,2,8 we evalu-
ated whether a prophylactic treatment with simvastatin mod-
ulates mRNA expression of IL-1 and TNF-, 2 proinflam-
matory cytokines that appear to contribute to neuronal
damage after stroke, and of the anti-inflammatory cytokine
IL-10. A marked activation of IL-1 and TNF- mRNA
Figure 1. Effect of different schedules of sim-
vastatin (Sim) treatment and neonatal HI on
body weight measured at 21 (A) and 80 days
(B) of age. Data are meanSE. *P0.05,
¶P0.001 compared with control group.
Figure 2. Effect of different schedules of simvastatin (Sim) treat-
ment and neonatal HI on left and right choices in a T-maze. Ani-
mals were tested at 28 to 30 days of age. Results represent the
right/left choice ratio and are expressed as meanSE. *P0.05
compared with control group; ¶P0.05 compared with HI
group.
Figure 3. Effect of different schedules of simvastatin (Sim) treat-
ment and neonatal HI on circular water maze performances.
Animals were assessed with a training-to-criterion test, as
described in Materials and Methods. Results represent the num-
ber of sessions needed to reach the criterion and are expressed
as meanSE. Results for first (1) and second (s) positions of the
pedestal are shown (P0.0028 and P0.0042, respectively;
Kruskal-Wallis test). *P0.01, ¶P0.05 compared with control
group (Dunn multiple comparison test).
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expression was induced in neonatal rat cortex 4 hours after HI
(Figure 5). Simvastatin treatment partially prevented this
activation. In the cortex of animals in the HI-simvastatin 1–7
group, IL-1 and TNF- mRNA expression was not signif-
icantly increased. IL-1 and TNF- activation was no longer
present 24 hours after HI in any experimental groups (data not
shown). In the same animals IL-10 mRNA was also mea-
sured, and no significant changes were found in any experi-
mental group (data not shown).
No differences in cholesterol levels were found in 7-day-
old animals (116.06 and 96.010 mg/dL in control and
HI-simvastatin 1–7 groups, respectively) or in adult animals
(63.213 and 63.018 mg/dL in control and HI-simvastatin
1–7 groups, respectively).
Regional Volume Measurements of 80-Day-Old Ischemic and Simvastatin-Treated
Ischemic Animals
n
Whole
HemisphereY CortexY HippocampusY
Ischemic animals
Left 7 494.230.2 121.410.5 41.94.7
Right 7 270.519.9¶ 50.76.2¶ 18.52.5¶
% ipsilateral damagey 45.31.9 57.74.2 55.243.3
HI-simvastatin 1–7 group
Left 7 462.215.6 119.110.4 39.32.4
Right 7 364.833.4§ 84.612.1§ 28.13.0§
% ipsilateral damagey 21.17.1** 29.55.9** 27.97.6**
HI-simvastatin 4–11 group
Left 7 472.631.1 116.715.3 38.03.3
Right 7 383.636.2 89.717.4 30.44.9
% ipsilateral damagey 18.85.6** 21.78.0** 23.35.6**
HI-simvastatin 7–14 group
Left 7 438.125.4 111.68.8 34.93.2
Right 7 259.128.9¶ 48.0712.9¶ 20.32.6¶
% ipsilateral damagey 38.49.3 53.813.4 39.110.2
Simvastatin (20 mg/kg) was administered from postnatal day 1 to day 7. Y, measured in cubic
millimeters; y, percent ipsilateral damage was calculated from bilateral regional volumes, using the
formula: 100(LR)/L, where Lleft-sided volume and Rright-sided volume.
§P0.05 and ¶P0.001, Mann-Whitney U test comparing lesioned side to the nonlesioned side.
**P0.05 comparing the % ipsilateral damage of ischemic animals with simvastatin-treated
ischemic animals (Kruskal-Wallis test followed by the Dunn multiple comparison test).
Figure 4. Western blot analysis of eNOS expression in cerebral cortex of rats in control, HI, and HI-simvastatin (Sim) 1–7 groups evalu-
ated at 6 hours (A), 24 hours (B), and 5 days (C) after the end of the HI insult. Data are expressed as percentage of optical density
detected for the respective group of control animals and are meanSE of 5 animals. The immunoblots for eNOS and -actin (as an
internal standard) reported above each graph are representative of 3 independent experiments. Exposure times of the blots were not
identical. R indicates damaged side; L, contralateral side. *P0.05 compared with control group.
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Discussion
In the present study we have shown that prophylactic but not
delayed administration of simvastatin, a statin that crosses the
blood-brain barrier, significantly protects from brain damage
and its behavioral consequences in a neonatal model of HI. In
agreement with our previous work,12 the neuroprotective
effect of simvastatin was found to be long-lasting and to
occur under conditions that resulted in severe tissue injury in
most ischemic animals. Simvastatin did not induce any
significant reduction in body weight since it did not differ
from that observed in HI vehicle-treated animals and was
completely recovered in the adult animals. Furthermore,
neuroprotection occurred without a significant alteration in
blood cholesterol levels measured both at the end of the
treatment and at the adult age, indicating that neuroprotection
is independent of the lipid effects of the drug.
The behavioral asymmetry and learning deficits observed
in adult ischemic animals were significantly attenuated by
1-week pretreatment or 3-day pretreatment followed by a
4-day posttreatment with simvastatin but not when simvasta-
tin was administered for 1 week immediately after the
ischemic insult. These results are consistent with the finding
that animals in the HI-simvastatin 1–7 and HI-simvastatin
4–11 groups, but not those in the HI-simvastatin 7–14 group,
developed smaller infarctions and indicate that a prophylactic
treatment is necessary to obtain neuroprotection. Our findings
are in agreement with those previously reported in adult mice
after middle cerebral artery occlusion and reperfusion show-
ing that statins are effective only when administered before
the ischemic insult.5,15 In a recent study, however, using MRI
techniques, we confirmed the preventive neuroprotective
effect of statins after permanent middle cerebral artery
occlusion in adult rats and reported that simvastatin was also
protective when administered immediately after the ischemic
insult.16 The fact that the neuroprotective effect of simvastatin
can be observed with different schedules of drug administra-
tion may be due to the different experimental models of HI
used in which different mechanisms may be involved in the
evolution of ischemic injury (mouse versus rat and transient
versus permanent middle cerebral artery occlusion). This may
be particularly important when adult and immature animals
are compared because the temporal progression of the injury
appears to be faster in the newborn than in the adult.17 A
question that still remains open and that deserves further
investigation is the neuroprotective effect of a shorter sched-
ule or a single prophylactic administration of the drug.
Indeed, shortening the length of the treatment and decreasing
the total amount of the drug would reduce the risk of toxic
effects and make clinical use possible under conditions in
which the risk of stroke is foreseeable and particularly high.
Several studies performed in adult animals reported that
statins may exert their neuroprotective effect by increasing
eNOS expression and activity in endothelial cells.5,6,15 NO
produced by eNOS, indeed, might orchestrate paracrine
homeostatic functions of the endothelium such as inhibition
of leukocyte and platelet adhesion and control of vascular
tone. Herein, we have shown that in the cerebral cortex of
immature rats, eNOS expression was increased in the dam-
aged side of HI animals 24 hours after the insult and returned
to control values after 5 days, suggesting that eNOS induction
may represent a reactive response that probably plays a role
in protecting tissue from additional ischemic damage. Treat-
ment with simvastatin, however, was not able to further
increase the expression of the protein, suggesting that, at least
in immature animals, the neuroprotective effect may result
from additional actions of the drug. Indeed, statins produce
Figure 5. IL-1 and TNF- mRNA expression in
cerebral cortex 4 hours after HI. A, Representative
gels obtained for cyclophilin (Cycloph), IL-1, and
TNF-. B, Amount of cytokine mRNA is expressed
as ratio of densitometric measurements (optical
density [OD]) of samples to corresponding reporter
gene. Data are meanSE of 5 rats. Sim indicates
simvastatin. *P0.05 compared with control group.
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pleiotropic effects, which are also mediated by NO produc-
tion,3,4,18 and it is possible that the relative contribution of
these actions on their neuroprotective effect may change
during brain maturation. The anti-inflammatory and immu-
nomodulatory effects of statins, in particular, may play an
important role in the neuroprotective activity in immature
animals. There is evidence, indeed, that statins inhibit both
acute and chronic inflammation probably by interfering with
endothelial adhesion and transendothelial migration of leuko-
cytes to sites of inflammation2. In primary astrocytes, micro-
glia, and macrophages, statins were found to reduce the
induction of inflammatory mediators such as TNF-, IL-1,
and interleukin-6.8 The expression of TNF- and IL-1, on
the other hand, is increased after focal cerebral ischemia in
the neonatal rat,19 and pharmacological strategies aimed at
reducing the activity of these pro-inflammatory cytokines
attenuate tissue damage.20 In the present study we found that
the expression of mRNA for the 2 proinflammatory cytokines
IL-1 and TNF- was significantly increased in HI but not in
HI-simvastatin 1–7 animals. Thus, in immature animals the
anti-inflammatory properties of simvastatin could play an
important role in its neuroprotective effect, resulting in
reduction of infiltrating leukocytes and production of proin-
flammatory cytokines in the degenerating tissue. In this
regard, it has recently been demonstrated that simvastatin
attenuates leukocyte–endothelial cell interactions only after
pretreatment with the drug,21 and this may explain why, in
our study, pharmacological treatment after HI was not
neuroprotective.
In conclusion, the studies described in this report indicate
that prophylactic but not delayed administration of simvasta-
tin leads to an improvement in functional outcome in neonatal
stroke. The reduced induction of IL-1 and TNF- mRNA
suggests that the neuroprotective effect of statins during brain
development may be related to a dampening of the inflam-
matory response.
Most perinatal strokes are unforeseeable events. The find-
ing that the effect of simvastatin can be detected only if the
drug is administered before the ischemic insult suggests that
statins may be helpful in conditions in which the risk is
particularly high, such as in children undergoing cardiac
surgery for congenital heart diseases. Experiments are in
progress to assess the lowest dosage and the optimal schedule
of simvastatin administration resulting in neuroprotection in
immature rats.
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